Zenosense Inc (ZENO) 0.0203 $ZENO
Zenosense, Inc. - Hospital Collaboration - 400 Person Lung Cancer Detection Trial
Marketwired - Wed Dec 17, 7:30AM CST
Zenosense, Inc. (OTCQB: ZENO) ("Zenosense", the "Company"
, a healthcare technology company primarily focused on developing and marketing devices to detect the MRSA "Super-Bug" and to detect signs of lung cancer in exhaled breath, is pleased to announce that on 16 December 2014, the Company's development partner, Zenon Biosystem (Zenon) entered into a collaboration agreement for a lung cancer detection trial. The agreement is with a university and a large university hospital located in the region of Madrid, Spain. The trial will facilitate clinical tests on breath samples from 400 people, in line with the previously announced protocol design.
Zenosense, Inc.; Stock Now DTC DWAC/FAST Eligible
Marketwired - Thu Dec 04, 7:30AM CST
Zenosense, Inc. (OTCQB: ZENO) ("Zenosense", the "Company", a healthcare technology company primarily focused on developing and marketing devices to detect the MRSA "Super-Bug" and to detect signs of lung cancer in exhaled breath, is pleased to announce that Depository Trust Corporation (DTC) has approved Zenosense common stock for DWAC/FAST transfer through Zenosense's transfer agent, Action Stock Transfer Corporation.
These Medical Stocks Are Reaching A Fever Pitch Following Midterm Elections
ACCESSWIRE - Wed Nov 12, 8:53AM CST
CORAL GABLES, FL / ACCESSWIRE / November 12, 2014 / The midterm elections are still fresh in our minds and as several sectors have suffered due to the Republican party taking control, others have prospered. Moreover medical stocks have benefited greatly from this recent turn-over of power on Capitol Hill as certain changes are being made to the Affordable Care Act. Over the last week, companies involved in the healthcare and biotech sectors have enjoyed more of a marketwide revival in stock price appreciation.
AEMD: 6.50 (-0.10)
Zenosense, Inc. Reports Manufacturing of Pre-Commercial Lung Cancer Detection Device
Marketwired - Tue Nov 04, 7:34AM CST
Zenosense, Inc. (OTCQB: ZENO) ("Zenosense," the "Company", a healthcare technology company primarily focused on developing and marketing devices to detect the MRSA "Super-Bug" and to detect signs of lung cancer in exhaled breath, is pleased to announce the manufacturing of a pre-commercial prototype device to be evaluated for the detection of lung cancer in exhaled breath ("Device".
Zenosense, Inc.; MRSA/SA Prototype Achieves over 95% Sensibility in Cultured Headspace
ACCESSWIRE - Mon Oct 27, 8:30AM CDT
VALENCIA, SPAIN / ACCESSWIRE / Ocotber 27, 2014 / Zenosense, Inc. (OTCQB: ZENO) ("Zenosense", the "Company", a healthcare technology company primarily focused on developing and marketing devices to detect the MRSA "Super-Bug" and to detect signs of lung cancer in exhaled breath, is pleased to announce considerable progress made in the development of its MRSA/SA detector. The prototype device successfully achieved a sensibility detection rate greater than 95% on cultured headspace in a series of tests over a two week period in a clinical setting.
Zenosense, Inc.; Protocol Design -- Lung Cancer Detection Tests
Marketwired - Tue Oct 21, 8:32AM CDT
Zenosense, Inc. (OTCQB: ZENO) ("Zenosense", the "Company", a healthcare technology company primarily focused on developing and marketing devices to detect the MRSA "Super-Bug" and to detect signs of lung cancer in exhaled breath, is pleased to announce the completion of protocol design of a significant lung cancer detection trial to be carried out in a clinical setting.
Zenosense, Inc. - Hospital Collaboration - 400 Person Lung Cancer Detection Trial
Marketwired - Wed Dec 17, 7:30AM CST
Zenosense, Inc. (OTCQB: ZENO) ("Zenosense", the "Company"
, a healthcare technology company primarily focused on developing and marketing devices to detect the MRSA "Super-Bug" and to detect signs of lung cancer in exhaled breath, is pleased to announce that on 16 December 2014, the Company's development partner, Zenon Biosystem (Zenon) entered into a collaboration agreement for a lung cancer detection trial. The agreement is with a university and a large university hospital located in the region of Madrid, Spain. The trial will facilitate clinical tests on breath samples from 400 people, in line with the previously announced protocol design. Zenosense, Inc.; Stock Now DTC DWAC/FAST Eligible
Marketwired - Thu Dec 04, 7:30AM CST
Zenosense, Inc. (OTCQB: ZENO) ("Zenosense", the "Company"
, a healthcare technology company primarily focused on developing and marketing devices to detect the MRSA "Super-Bug" and to detect signs of lung cancer in exhaled breath, is pleased to announce that Depository Trust Corporation (DTC) has approved Zenosense common stock for DWAC/FAST transfer through Zenosense's transfer agent, Action Stock Transfer Corporation. These Medical Stocks Are Reaching A Fever Pitch Following Midterm Elections
ACCESSWIRE - Wed Nov 12, 8:53AM CST
CORAL GABLES, FL / ACCESSWIRE / November 12, 2014 / The midterm elections are still fresh in our minds and as several sectors have suffered due to the Republican party taking control, others have prospered. Moreover medical stocks have benefited greatly from this recent turn-over of power on Capitol Hill as certain changes are being made to the Affordable Care Act. Over the last week, companies involved in the healthcare and biotech sectors have enjoyed more of a marketwide revival in stock price appreciation.
AEMD: 6.50 (-0.10)
Zenosense, Inc. Reports Manufacturing of Pre-Commercial Lung Cancer Detection Device
Marketwired - Tue Nov 04, 7:34AM CST
Zenosense, Inc. (OTCQB: ZENO) ("Zenosense," the "Company"
, a healthcare technology company primarily focused on developing and marketing devices to detect the MRSA "Super-Bug" and to detect signs of lung cancer in exhaled breath, is pleased to announce the manufacturing of a pre-commercial prototype device to be evaluated for the detection of lung cancer in exhaled breath ("Device". Zenosense, Inc.; MRSA/SA Prototype Achieves over 95% Sensibility in Cultured Headspace
ACCESSWIRE - Mon Oct 27, 8:30AM CDT
VALENCIA, SPAIN / ACCESSWIRE / Ocotber 27, 2014 / Zenosense, Inc. (OTCQB: ZENO) ("Zenosense", the "Company"
, a healthcare technology company primarily focused on developing and marketing devices to detect the MRSA "Super-Bug" and to detect signs of lung cancer in exhaled breath, is pleased to announce considerable progress made in the development of its MRSA/SA detector. The prototype device successfully achieved a sensibility detection rate greater than 95% on cultured headspace in a series of tests over a two week period in a clinical setting. Zenosense, Inc.; Protocol Design -- Lung Cancer Detection Tests
Marketwired - Tue Oct 21, 8:32AM CDT
Zenosense, Inc. (OTCQB: ZENO) ("Zenosense", the "Company"
, a healthcare technology company primarily focused on developing and marketing devices to detect the MRSA "Super-Bug" and to detect signs of lung cancer in exhaled breath, is pleased to announce the completion of protocol design of a significant lung cancer detection trial to be carried out in a clinical setting. 
